MX2020003286A - Nuevas terapias para tratar y prevenir la rinosinusitis crónica. - Google Patents
Nuevas terapias para tratar y prevenir la rinosinusitis crónica.Info
- Publication number
- MX2020003286A MX2020003286A MX2020003286A MX2020003286A MX2020003286A MX 2020003286 A MX2020003286 A MX 2020003286A MX 2020003286 A MX2020003286 A MX 2020003286A MX 2020003286 A MX2020003286 A MX 2020003286A MX 2020003286 A MX2020003286 A MX 2020003286A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- chronic rhinosinusitis
- preventing chronic
- novel therapies
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
- A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona composiciones y métodos para romper la biopelícula bacteriana preformada o prevenir la formación de la biopelícula bacteriana; además, se proporcionan en la invención métodos y composiciones para tratar y prevenir la rinosinusitis crónica; tales composiciones y métodos usan uno o más compuestos antibióticos en combinación con al menos un compuesto de fosfolípido descrito en la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762561313P | 2017-09-21 | 2017-09-21 | |
PCT/US2018/052269 WO2019060761A1 (en) | 2017-09-21 | 2018-09-21 | NEW THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINO-SINUSITIS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003286A true MX2020003286A (es) | 2020-10-01 |
Family
ID=65810526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003286A MX2020003286A (es) | 2017-09-21 | 2018-09-21 | Nuevas terapias para tratar y prevenir la rinosinusitis crónica. |
Country Status (9)
Country | Link |
---|---|
US (1) | US11413297B2 (es) |
EP (1) | EP3684180A4 (es) |
JP (1) | JP2020534333A (es) |
AU (1) | AU2018335869B2 (es) |
CA (1) | CA3076615A1 (es) |
IL (1) | IL273431B2 (es) |
MX (1) | MX2020003286A (es) |
SG (1) | SG11202002600VA (es) |
WO (1) | WO2019060761A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165997A (en) * | 1997-11-20 | 2000-12-26 | Statens Serum Institut | Phospholipids having antimicrobial activity with or without the presence of antimicrobials |
US20030139356A1 (en) * | 2001-05-18 | 2003-07-24 | Persing David H. | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds |
US8859524B2 (en) * | 2005-11-17 | 2014-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Lipid conjugates in the treatment of chronic rhinosinusitis |
JP5232009B2 (ja) * | 2005-12-19 | 2013-07-10 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された細胞毒性を有するアルキルリン脂質誘導体並びにそれらの使用 |
ES2666276T3 (es) | 2006-10-11 | 2018-05-03 | Laboratoires Smb Sa | Composición farmacéutica antiinfecciosa para inhalación |
KR101315483B1 (ko) | 2011-06-23 | 2013-10-07 | 주식회사 아리바이오 | 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 |
WO2013135571A1 (en) | 2012-03-14 | 2013-09-19 | Orphanidis Pharma Research Gmbh | Compositions with enhanced therapeutic efficacy against infective agents of the eye comprising miltefosine and polyhexamethylene biguanide |
EP2923710A1 (en) | 2014-03-27 | 2015-09-30 | Universitätsklinikum Heidelberg | Bacterial phospholipase inhibitors as modulator of colonic bacterial flora |
EP3673899A1 (en) | 2015-02-17 | 2020-07-01 | Eli Lilly And Co. | Nasal powder formulation for treatment of hypoglycemia |
-
2018
- 2018-09-21 EP EP18858446.0A patent/EP3684180A4/en active Pending
- 2018-09-21 CA CA3076615A patent/CA3076615A1/en active Pending
- 2018-09-21 US US16/649,534 patent/US11413297B2/en active Active
- 2018-09-21 JP JP2020516746A patent/JP2020534333A/ja active Pending
- 2018-09-21 MX MX2020003286A patent/MX2020003286A/es unknown
- 2018-09-21 SG SG11202002600VA patent/SG11202002600VA/en unknown
- 2018-09-21 AU AU2018335869A patent/AU2018335869B2/en active Active
- 2018-09-21 WO PCT/US2018/052269 patent/WO2019060761A1/en unknown
-
2020
- 2020-03-19 IL IL273431A patent/IL273431B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202002600VA (en) | 2020-04-29 |
EP3684180A1 (en) | 2020-07-29 |
JP2020534333A (ja) | 2020-11-26 |
IL273431B2 (en) | 2023-06-01 |
IL273431A (en) | 2020-05-31 |
AU2018335869B2 (en) | 2024-06-13 |
AU2018335869A1 (en) | 2020-05-07 |
EP3684180A4 (en) | 2021-07-07 |
US20200306274A1 (en) | 2020-10-01 |
US11413297B2 (en) | 2022-08-16 |
CA3076615A1 (en) | 2019-03-28 |
WO2019060761A1 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020005772A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018015761A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2021000077A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006239A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006398A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006399A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016529A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016564A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016560A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016525A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12018500494A1 (en) | Car t cell therapies with enhanced efficacy | |
ZA201807256B (en) | Inhibitors of activin receptor-like kinase | |
MD3804737T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
WO2015120062A8 (en) | Therapeutic compounds and compositions | |
MD3600363T2 (ro) | Compoziții cuprinzând tulpini bacteriene | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
MX2020004118A (es) | Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas. | |
ZA202102702B (en) | Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same | |
MX2018011046A (es) | Composiciones y metodos para tratar canceres. | |
MX2018003301A (es) | Inhibidores de pcna. | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED |